Powder: -20°C for 3 years | In solvent: -80°C for 1 year
THI0019 is a highly potent agonist of the integrin α4β1 (VLA-4) receptor, with an EC 50 range of 1-2 μM. It effectively promotes the adhesion of stem/progenitor cells. Furthermore, THI0019 successfully modulates adhesion processes mediated by α4β7, α5β1, and αLβ2 integrins.
产品描述 | THI0019 is a highly potent agonist of the integrin α4β1 (VLA-4) receptor, with an EC 50 range of 1-2 μM. It effectively promotes the adhesion of stem/progenitor cells. Furthermore, THI0019 successfully modulates adhesion processes mediated by α4β7, α5β1, and αLβ2 integrins. |
靶点活性 | α4β1:1-2 μM (EC50) |
体外活性 | In cell adhesion assays in which Jurkat cells bound to CS1-conjugated BSA, THI0019 shows a dose-dependent enhancement in cell binding with an EC 50 of 1.7 μM. When VCAM-1 is used as the ligand, THI0019 induces an even more pronounced 100-fold increase in Jurkat cell binding, with an EC 50 of 1.2 μM. THI0019 induces a dose-dependent increase in EPC binding to VCAM-1 (EC 50 of 3.7 μM). THI0019 facilitates the rolling and spreading of cells on VCAM-1 and the migration of cells toward SDF-1α[1]. |
别名 | THI0019 |
分子量 | 601.73 |
分子式 | C29H35N3O7S2 |
CAS No. | 1378532-99-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
THI0019 1378532-99-0 THI-0019 THI 0019 Inhibitor inhibitor inhibit